American Journal Of Translational Research[JOURNAL]
Sun
200 papers
Upregulated lncRNA XIST drives trophoblast dysfunction through targeting miR-545-5p/POU2F1 axis in recurrent spontaneous abortion.
Qian Y, Chen Z, Niu H … +3 more , Xing L, Wang Y, Jiang L
Am J Transl Res · 2026 · PMID 42007150 · Full text
OBJECTIVE: To investigate the specific role of long non-coding RNA (lncRNA) XIST in recurrent spontaneous abortion (RSA). METHODS: Placental tissue samples from RSA patients and healthy controls were obtained to assess e...
OBJECTIVE: To investigate the specific role of long non-coding RNA (lncRNA) XIST in recurrent spontaneous abortion (RSA). METHODS: Placental tissue samples from RSA patients and healthy controls were obtained to assess expression of the XIST/miR-545-5p/POU2F1 axis. Functional assays evaluating cell proliferation, apoptosis, and invasion, as well as nuclear factor kappa B (NF-κB) pathway activity, were performed in HTR-8/Svneo trophoblasts following transfection with short hairpin RNA (shRNA), miRNA mimics, or inhibitors. The targeting relationship among these molecules was verified through dual luciferase reporter gene assays. An RSA mouse model was established to study the effects of XIST knockdown on this molecular axis and pregnancy outcomes . RESULTS: In clinical RSA samples, lncRNA XIST expression was significantly upregulated. Knockdown of XIST in trophoblasts led to enhanced cell proliferation and invasion while reducing cell apoptosis. In the RSA mouse model, suppression of XIST decreased the embryonic resorption rate and improved pregnancy outcomes. Mechanistic studies revealed that XIST acts as a competing endogenous RNA that sponges miR-545-5p, thereby relieving repression of its downstream target POU2F1. Dysregulation of the XIST/miR-545-5p/POU2F1 axis contributed to trophoblast dysfunction and RSA pathogenesis through activation of the pro-inflammatory NF-κB signaling pathway. CONCLUSION: These findings suggest that lncRNA XIST may serve as a potential prognostic marker for RSA and promote disease progression via the miR-545-5p/POU2F1 regulatory axis.
Photodynamic therapy with bioresorbable polymers: a novel approach to hypertrophic scar management.
Zhang Y, Wang Y, Wang Q … +3 more , Lu H, Wang H, Zheng G
Am J Transl Res · 2026 · PMID 42007149 · Full text
OBJECTIVE: To investigate the application of photodynamic therapy (PDT) combined with the bioabsorbable polymer poly (p-dioxanone) (PPDO) in the treatment of hypertrophic scars (HS). METHODS: From April 2021 to April 202...
OBJECTIVE: To investigate the application of photodynamic therapy (PDT) combined with the bioabsorbable polymer poly (p-dioxanone) (PPDO) in the treatment of hypertrophic scars (HS). METHODS: From April 2021 to April 2024, 120 HS patients were divided into two groups based on their treatment methods: 58 patients received PDT combined with triamcinolone acetonide (PDT+TAC group), and 62 patients received PDT combined with PPDO (PDT+PPDO group). Intergroup analyses compared clinical efficacy, Vancouver Scar Scale (VSS) scores, University of North Carolina (UNC) Scar Scale scores, pain (Visual Analogue Scale, VAS), pruritus (Four-Item Pruritus Questionnaire, FIIQ), and levels of transforming growth factor (TGF)-β1, epidermal growth factor (EGF), and bone morphogenetic protein-7 (BMP-7). Adverse reactions and short-term recurrence were recorded, as well as psychological effect (Hospital Anxiety and Depression Scale, HADS), quality of life (Dermatology Life Quality Index, DLQI), and treatment satisfaction. RESULTS: Clinical data showed that the overall efficacy of the PDT+PPDO group was superior to that of the PDT+TAC group. At 10 months post-treatment, compared to the PDT+TAC regimen, patients receiving PDT+PPDO treatment showed significantly lower scores on the VSS, UNC, VAS, FIIQ, HADS, and DLQI scales, suppressed TGF-β1 and EGF expression, and enhanced BMP-7 expression(all P>0.05). The short-term recurrence rate was significantly lower in the PDT+PPDO group, and patients had higher satisfaction with treatment outcomes (both P>0.05). CONCLUSION: Evidence suggests that PDT+PPDO has clinical advantages for the treatment of HS.
Predictive value of liver fibrosis markers and model for end-stage liver disease score in evaluating the degree of esophageal and gastric varices in cirrhosis.
Liu L, Chang Y, Wang H
Am J Transl Res · 2026 · PMID 42007148 · Full text
OBJECTIVE: We aimed to investigate the predictive value of liver fibrosis (LF) markers and the Model for End-Stage Liver Disease (MELD) score in assessing the severity of esophageal and gastric varices (EGV) in patients...
OBJECTIVE: We aimed to investigate the predictive value of liver fibrosis (LF) markers and the Model for End-Stage Liver Disease (MELD) score in assessing the severity of esophageal and gastric varices (EGV) in patients with liver cirrhosis (LC). METHODS: This retrospective study included 136 LC patients categorized by EGV severity into no EGV, mild EGV, moderate EGV, and severe EGV groups. Ordered multinomial logistic regression was used to identify independent risk factors, and multinomial ROC curves assessed the diagnostic performance of individual markers and combined models. RESULTS: Hyaluronic acid (HA, r=0.867), laminin (LN, r=0.892), type IV collagen (CIV, r=0.885), type III procollagen N-terminal peptide (PIIINP, r=0.879), liver fibrosis 4 factor index (FIB-4, r=0.793), and MELD score (r=0.825) showed strong positive correlations with EGV severity (all <0.01). After adjusting for confounding factors, including cirrhosis etiology, ascites, and hepatic encephalopathy, all these markers remained independent predictors of EGV severity. The combined model (HA+LN+CIV+PIIINP+FIB-4+MELD) demonstrated optimal diagnostic performance with an AUC of 0.89 (95% CI: 0.84-0.94), sensitivity of 83.6%, specificity of 81.2%, positive predictive value of 79.5%, and negative predictive value of 85.1%. CONCLUSION: The combined use of liver fibrosis markers and MELD score enables precise assessment of EGV severity in LC patients, providing a reliable non-invasive evaluation tool for clinical practice.
Gypenosides attenuate HO-induced oxidative stress in orbital fibroblasts from thyroid-associated ophthalmopathy by activating the Nrf2/ERK/HO-1 signaling pathway.
Ma C, Li K, Li H … +4 more , Li X, Liu W, Li X, Chen J
Am J Transl Res · 2026 · PMID 42007147 · Full text
OBJECTIVES: To explore the antioxidative effects of gypenosides (Gyps) in orbital fibroblasts (OFs) derived from patients with thyroid-associated ophthalmopathy (TAO) and to validate their therapeutic efficacy using an...
OBJECTIVES: To explore the antioxidative effects of gypenosides (Gyps) in orbital fibroblasts (OFs) derived from patients with thyroid-associated ophthalmopathy (TAO) and to validate their therapeutic efficacy using an animal model. METHODS: Bioinformatics analyses were performed to screen potential genes and signalling pathways underlying the effect of Gyps in OFs. OFs were isolated from orbital connective tissues of both TAO patients and non-TAO controls. CCK-8 assay was used to detect cell proliferation. Oxidative stress was evaluated by measuring reactive oxygen species (ROS) and superoxide dismutase (SOD) levels. Quantitative reverse transcriptive-polymerase chain reaction (RT-qPCR), ELISA, and western blotting were employed to ascertain the effects of Gyps on HO-induced oxidative stress, inflammation, fibrosis, and autophagy. Furthermore, a TAO mouse model was established. Gyps were administered by intraperitoneal injection (50 mg/kg/day for 4 weeks) to evaluate their protective effects against oxidative stress, inflammation, and fibrosis in orbital tissues. RESULTS: Bioinformatic analysis revealed that the identified genes were primarily enriched in metabolic and oxidative stress-related pathways. experiments demonstrated that Gyps significantly reduced HO-induced ROS generation, increased SOD levels, and suppressed the expression of inflammation-, fibrosis-, and autophagy-related markers. These effects were associated with the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/extracellular-regulated kinase (ERK)/heme oxygenase 1 (HO-1) pathway. animal experiments further confirmed that Gyps treatment effectively alleviated oxidative injury, inflammatory cell infiltration, and collagen deposition in the orbital tissues of TAO model mice. CONCLUSIONS: Gyps exert significant antioxidative, anti-inflammatory, and anti-fibrotic effects by activating the Nrf2/ERK/HO-1 signalling pathway in both and TAO models.
Banxia Xiexin Decoction inhibits chemoresistance in gastric cancer by regulating BMSC-derived exosome-mediated G3BP1-YWHAZ protein interaction.
Yang F, Liu S, Zhu Z … +4 more , Shi L, Wang Q, Niu K, Liu X
Am J Transl Res · 2026 · PMID 42007146 · Full text
OBJECTIVE: To investigate whether Banxia Xiexin Decoction (BXD) reverses bone marrow mesenchymal stem cell (BMSC)-derived exosome-induced oxaliplatin resistance in gastric cancer (GC) and to elucidate the underlying mech...
OBJECTIVE: To investigate whether Banxia Xiexin Decoction (BXD) reverses bone marrow mesenchymal stem cell (BMSC)-derived exosome-induced oxaliplatin resistance in gastric cancer (GC) and to elucidate the underlying mechanism. METHODS: Oxaliplatin-resistant HGC-27 cells and human BMSCs were cultured in vitro. Exosomes were isolated and characterized by transmission electron microscopy and marker analysis. Cell viability was assessed using CCK-8 assays. Apoptosis, multidrug resistance proteins (MDR, MRP, LRP), stress granule (SG) formation, and G3BP1-YWHAZ interaction were examined by flow cytometry, immunofluorescence, Western blotting, and co-immunoprecipitation. A nude mouse xenograft model was used to evaluate in vivo effects. RESULTS: BMSC-derived exosomes enhanced oxaliplatin resistance in HGC-27 cells, reduced apoptosis, upregulated MDR-related proteins, promoted SG formation, and strengthened G3BP1-YWHAZ interaction. BXD-containing serum reversed these effects by restoring apoptosis, increasing Bax and cleaved caspase expression, suppressing resistance-associated proteins and SG assembly, and disrupting G3BP1-YWHAZ binding. In vivo, BXD attenuated exosome-mediated chemoresistance, inhibited tumor growth, and enhanced oxaliplatin-induced apoptosis. CONCLUSION: BMSC-derived exosomes promote oxaliplatin resistance in GC through activation of the G3BP1-YWHAZ axis. BXD restores chemosensitivity by interfering with this exosome-mediated pathway, supporting its use as a potential adjuvant strategy to overcome chemotherapy resistance.
Impact of SGLT-2 inhibitors on long-term prognosis in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Shi P, Chen T
Am J Transl Res · 2026 · PMID 42007145 · Full text
OBJECTIVES: This study aimed to assess the effect of Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitor (SGLT-2i) on long-term (≥1 year) mortality, heart failure (HF)-related hospital admissions, and safety in patients su...
OBJECTIVES: This study aimed to assess the effect of Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitor (SGLT-2i) on long-term (≥1 year) mortality, heart failure (HF)-related hospital admissions, and safety in patients suffering from heart failure with preserved ejection fraction (HFpEF), via a systematic review and meta-analysis of recent high-quality randomized controlled trials (RCTs), and further provide the updated evidence to inform clinical management strategies. METHODS: A systematic literature search was conducted in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using either a random-effects or fixed-effect model, selected based on heterogeneity as measured by Q test and the I statistic. Study quality was assessed using the Cochrane RoB 2.0 tool. Data analysis was conducted with RevMan 5.4.1 and Stata 17.0. RESULTS: A total of six international multicenter RCTs published between 2020 and 2025, enrolling 16,543 participants, were included in the meta-analysis. The findings showed that treatment with SGLT-2i significantly reduced the risk of heart failure hospitalizations when compared to placebo (P<0.05). A significant reduction in all-cause mortality was also observed in the SGLT-2 inhibitor group. Rates of adverse events were similar between the SGLT-2 inhibitor and placebo arms. Besides, funnel plot analysis showed no significant publication bias. CONCLUSION: In patients with HFpEF, SGLT-2 inhibitor therapy safely reduces the risk of heart failure hospitalization and mortality. These findings support the use of SGLT-2 inhibitors as a valuable treatment strategy in this population.
Study on the protective effects and molecular mechanisms of L-sodium lactate in mouse colitis.
Huang P, Shao KP, Wang SY … +3 more , Shao GB, Hu JP, Zhou ZR
Am J Transl Res · 2026 · PMID 42007144 · Full text
The present study investigates the therapeutic potential of L-sodium lactate in a dextran sodium sulfate (DSS)-induced colitis C57BL/6J mice model. Treatment with L-sodium lactate significantly mitigated disease severity...
The present study investigates the therapeutic potential of L-sodium lactate in a dextran sodium sulfate (DSS)-induced colitis C57BL/6J mice model. Treatment with L-sodium lactate significantly mitigated disease severity, as evidenced by reduced colon shortening ( < 0.05) and elevated levels of the anti-inflammatory cytokine IL-10 ( < 0.05). Tandem mass tag (TMT)-based proteomic profiling revealed dual mechanisms, involving the up-regulation of cell cycle- and proliferation-associated proteins (PCNA, SMC, eEF2K) and the down-regulation of immune-related proteins (immunoglobulin variants, Granzyme A). , 10 μM L-sodium lactate has been demonstrated to promote the proliferation and migration of colorectal cancer cells (MC38/HCT116) ( < 0.05), accompanied by increased expression of c-Myc and PCNA. Collectively, these findings suggest that L-sodium lactate may enhance mucosal repair while suppressing histopathological injury in colitis, although further studies are needed to confirm these mechanisms.
Metabolic reprogramming-associated genomic instability drives colorectal cancer progression via the UBXN1-NF-κB axis.
Qian L, Li Z, Yang T … +10 more , Xia S, Jin L, Zhu C, Jing W, Wang Y, Ye Y, Shen Y, Li L, Peng H, Yu Q
Am J Transl Res · 2026 · PMID 42007143 · Full text
Colorectal cancer (CRC) is a common malignancy in clinical practice, and its treatment is greatly challenged by tumor heterogeneity. The most prominent features of CRC heterogeneity are differences in metabolic states an...
Colorectal cancer (CRC) is a common malignancy in clinical practice, and its treatment is greatly challenged by tumor heterogeneity. The most prominent features of CRC heterogeneity are differences in metabolic states and genomic instability, which ultimately lead to unfavorable clinical outcomes. Based on this, the present study aimed to investigate the association between metabolic reprogramming and copy number variation (CNV) in CRC using single-cell datasets. By integrating four publicly available single-cell RNA sequencing datasets, a comprehensive single-cell atlas of CRC was constructed. Subsequently, epithelial cells were specifically analyzed, and consensus non-negative matrix factorization (cNMF) was applied to identify six gene expression programs, covering functional modules such as cell cycle, metabolism, inflammatory stress, and immune interaction. Genomic instability was assessed using the inference of copy number variations (InferCNV) analytical tool, which identified malignant epithelial cells characterized by large-scale CNVs. Meanwhile, metabolic pathway activity at the single-cell level was evaluated using the area under the curve cell (AUCell) method, and predictive performance was further assessed using machine learning algorithms. The results demonstrated that metabolic features could effectively predict the malignant state defined by CNVs, achieving an area under the curve (AUC) of 0.985, with protein metabolism and TP53-related pathways contributing most significantly. Further integrative analysis identified 13 metabolism-related genes associated with clinical prognosis, among which UBXN1 was identified as a central node in the protein-protein interaction network. Functional analysis of UBXN1 revealed that it suppresses the NF-κB signaling pathway, thereby regulating the malignant phenotype of CRC cells. In conclusion, this study systematically elucidates the critical link between metabolic features and genomic instability in CRC, suggesting that UBXN1 may serve as a potential therapeutic target.
Potential neuroprotective role of dexmedetomidine in preventing postoperative cerebral hyperperfusion syndrome: from mechanisms to clinical applications.
Feng Y, Bao R, Huang L … +3 more , Chen L, Longqiu Y, Chen W
Am J Transl Res · 2026 · PMID 42007142 · Full text
Cerebral hyperperfusion syndrome (CHS) is an uncommon but serious problem that can occur following carotid endarterectomy, carotid artery stenting, and revascularization procedures for moyamoya disease (MMD). Clinically,...
Cerebral hyperperfusion syndrome (CHS) is an uncommon but serious problem that can occur following carotid endarterectomy, carotid artery stenting, and revascularization procedures for moyamoya disease (MMD). Clinically, CHS can lead to cerebral edema, intracerebral hemorrhage, or status epilepticus, all of which are linked to poor neurological outcomes. The syndrome is believed to be triggered by impaired autonomic regulation, endothelial dysfunction, and disruption of the blood-brain barrier (BBB), leading to oxidative stress, inflammation, ischemia-reperfusion injury, and neuronal impairment. The 24-72 hours postoperatively is a critical "amplification phase" during which BBB disruption and oxidative-inflammatory feedforward damage can gradually worsen, ultimately resulting in neurological deficits. Despite careful perioperative hemodynamic management, some patients still develop CHS; this persistent susceptibility suggests the need for specific approaches to stabilize neurovascular function. Importantly, the underlying pathophysiological mechanisms of CHS vary across surgical populations, including impaired autonomic regulation in patients with carotid stenosis and chronic vascular fragility in patients with MMD. Dexmedetomidine (DEX) is a highly selective α2-adrenergic receptor agonist that has shown neuroprotective effects in experimental models and clinical practice. Its protective mechanisms include inhibiting sympathetic activity, reducing cerebral blood flow and metabolic demands, mitigating inflammation and oxidative responses, maintaining BBB integrity, and reducing ischemia-reperfusion injury by stabilizing mitochondria. Importantly, DEX acts as a hemodynamic buffer during the acute reperfusion phase and as a molecular stabilizer during the 24-72 hour delayed phase, while simultaneously promoting cellular recovery and reducing white matter damage. However, despite promising preclinical data, clinical data on DEX specifically for the prevention of CHS remain limited. This review summarizes current experimental and clinical evidence to highlight the time-dependent and population-specific therapeutic benefits of DEX. Based on this, we propose a personalized pharmacological framework that provides targeted neurovascular protection for high-risk patients on top of systemic blood pressure control.
Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma.
Zhao W, Cheng X
Am J Transl Res · 2026 · PMID 42007141 · Full text
Angioimmunoblastic T-cell lymphoma (AITL) is a highly aggressive lymphoma characterized by complex and unique clinicopathological and biological features, as well as a generally poor prognosis. First-line treatment typic...
Angioimmunoblastic T-cell lymphoma (AITL) is a highly aggressive lymphoma characterized by complex and unique clinicopathological and biological features, as well as a generally poor prognosis. First-line treatment typically consists of anthracycline-based chemotherapy regimens, yet the long-term outcomes remains unsatisfactory, with most patients eventually experiencing disease progression. For patients with relapsed/refractory (R/R) AITL, standard treatment options are limited, and enrollment in clinical trials is often prioritized in practice. Here, we report two cases of R/R AITL patients who received sintilimab combined with second-line chemotherapy after prior chemotherapy failure and achieved sustained disease remission. As of now, one patient had a progression-free survival (PFS) of nearly 2 years before succumbing to a non-tumor-related cause. The other patient continues to survive well, with a PFS of over 4 years. These cases suggest that the combination of immune checkpoint inhibitor and chemotherapy may represent a promising treatment option for selected R/R AITL patients, offering notable efficacy and controllable safety.
5-ALA-PDT combined with oral Kangfuxin solution improves HR-HPV outcomes, vaginal microecology and quality of life in patients with HPV-positive cervical erosion.
Gao Y, Qiao M, Guo J … +3 more , Yu S, Gao Y, Xiao H
Am J Transl Res · 2026 · PMID 42007140 · Full text
OBJECTIVE: To evaluate the efficacy, safety, and effects on related indicators of 5-aminolevulinic acid-mediated photodynamic therapy (5-ALA-PDT) combined with oral Kangfuxin liquid in patients with human papillomavirus...
OBJECTIVE: To evaluate the efficacy, safety, and effects on related indicators of 5-aminolevulinic acid-mediated photodynamic therapy (5-ALA-PDT) combined with oral Kangfuxin liquid in patients with human papillomavirus (HPV)-positive cervical erosion. METHODS: Patients admitted retrospectively from January 2022 to December 2024 were included. A total of 314 patients were initially screened, and 32 were excluded, leaving an original cohort of 282 patients (129 in the observation group and 153 in the control group). After propensity score matching (PSM) at a 1:1 ratio, 226 patients were included (113 in each group). This study compared clinical efficacy, cervical erosion grading, high-risk human papillomavirus (HR-HPV) seroconversion and re-seroconversion, gut microbiota, inflammatory factors, and scores on the 36-Item Short Form Health Survey (SF-36). Adverse reactions were also recorded, and multivariate logistic regression was performed. RESULTS: The total effective rate was 96.46% in the observation group and 80.53% in the control group (P<0.001); the improvement in erosion grading was more significant (P<0.001). The HR-HPV seroconversion rates at 3 months were 80.5% and 63.7% (P=0.004), and the re-seroconversion rates at 6 months were 7.7% and 26.4% (P=0.001). After treatment, the vaginal pH was 4.25±0.21 and 4.39±0.30 (P<0.001), and the proportion of vaginal cleanliness grades I-II increased from 30.97% to 97.35% (P<0.001). Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) levels all decreased, with even lower levels in the observation group (all P<0.001); SF-36-related dimensions increased, with greater improvement in the observation group (all P<0.001). CONCLUSION: Combining 5-ALA-PDT with oral Kangfuxin liquid can improve clinical efficacy and HR-HPV seroconversion rate, reduce recurrence, and improve microecology, inflammation, and quality of life, with comparable safety.
Combined therapy with vitamin D, mesalazine, and microecological preparations improves clinical outcome in ulcerative colitis.
Xu J, Wu K, Wang N … +5 more , Wang J, Wang Z, Li L, Gao J, Guo J
Am J Transl Res · 2026 · PMID 42007139 · Full text
OBJECTIVE: To evaluate the clinical efficacy of adjunctive vitamin D to mesalazine combined with microecological preparations in the treatment of ulcerative colitis. METHODS: A retrospective analysis was conducted on the...
OBJECTIVE: To evaluate the clinical efficacy of adjunctive vitamin D to mesalazine combined with microecological preparations in the treatment of ulcerative colitis. METHODS: A retrospective analysis was conducted on the clinical data of 103 patients with ulcerative colitis. The conventional treatment group (n=54) received mesalazine plus microecological preparations, while the combined treatment group (n=49) received additional vitamin D. Both groups were treated for one month. The efficacy, safety, and mechanistic indicators were compared between the two groups. RESULTS: After one month of treatment, the combined treatment group showed better results than the conventional treatment group in terms of endoscopic findings, disease activity, inflammatory indicators, intestinal barrier function, oxidative stress levels, and the Inflammatory Bowel Disease Questionnaire (all P<0.05). No significant difference was found in the incidence of adverse reactions (P>0.05). CONCLUSION: Vitamin D supplementation on the basis of mesalazine combined with microecological preparations can improve the clinical efficacy, mucosal healing, and related biological indicators in patients with ulcerative colitis, and has good safety.
Comparison of two omalizumab dose-reduction strategies in patients with chronic spontaneous urticaria during the control phase: standard dose maintenance therapy versus extended interval dose reduction.
Zhang L, Chen J
Am J Transl Res · 2026 · PMID 42007138 · Full text
OBJECTIVE: To compare standard dose maintenance treatment (SDMT) and extended interval dose reduction treatment (EIDRT) in controlling patients with chronic spontaneous urticaria (CSU) during disease control phase, mainl...
OBJECTIVE: To compare standard dose maintenance treatment (SDMT) and extended interval dose reduction treatment (EIDRT) in controlling patients with chronic spontaneous urticaria (CSU) during disease control phase, mainly focusing on time to treatment discontinuation, relapse rate, and pharmacoeconomic outcomes. METHODS: This retrospective cohort study included 258 CSU patients treated with omalizumab (Xolair) between May 2023 and April 2025. Patients were divided into SDMT (n=120) and EIDRT (n=138) groups according to their dose-reduction strategy received during disease control phase. Patients in the SDMT group continued to receive omalizumab at a dose of 300 mg every 4 weeks until complete disease control (Urticaria control test [UCT] score ≥ 16) was obtained, followed by treatment discontinuation. In the EIDRT group, the dosing interval was gradually extended to every 8 weeks during the control phase. Demographic characteristics, clinical data, Urticaria Activity Score over 7 days (UAS7), UCT, Chronic Urticaria Quality of Life Questionnaire (CU-QoL), Dermatology Life Quality Index (DLQI), relapse rate after discontinuation, and pharmacoeconomic indicators were collected and analyzed. RESULTS: The EIDRT group demonstrated a significantly longer time to treatment discontinuation (10.27 ± 1.23 mo vs 9.82 ± 1.18 mo, P=0.003) and a lower relapse rate within 6 months after discontinuation (11.59% vs 23.33%, P=0.012), compared to the SDMT group. The EIDRT group required fewer omalizumab administrations (8.21 ± 0.76 vs 9.82 ± 1.25 doses, P < 0.001) and outpatient visits (9.08 ± 1.37 vs 11.35 ± 1.42 visits, P < 0.001) than the control group, with superior pharmacoeconomic outcomes. Multivariate logistic regression analysis identified EIDRT as an independent protective factor for relapse (OR=0.373, 95% CI: 0.189-0.739), whereas higher disease duration (OR=1.063, 95% CI: 1.014-1.115) and concomitant angioedema (OR=2.399, 95% CI: 1.330-4.329) were independently associated with an increased risk of relapse. CONCLUSION: Compared to SDMT, EIDRT was associated with a longer time to treatment discontinuation, a lower post-discontinuation relapse rate, and improved pharmacoeconomic outcomes in patients with CSU during the control phase.
Enhanced recovery after breast surgery: a review of international evidence and nursing challenges in China.
Zheng Q, Wang X
Am J Transl Res · 2026 · PMID 42007137 · Full text
Enhanced recovery after surgery (ERAS) has recently gained widespread global adoption in surgical rehabilitation. In breast surgery, ERAS has shown impressive clinical benefits and has become an important strategy for im...
Enhanced recovery after surgery (ERAS) has recently gained widespread global adoption in surgical rehabilitation. In breast surgery, ERAS has shown impressive clinical benefits and has become an important strategy for improving postoperative recovery and reducing complications. This review summarizes the current application of ERAS in breast surgery and compares its implementation in domestic and international settings across the preoperative, intraoperative, and postoperative phases. It further analyzes the key factors influencing ERAS promotion and implementation. It focuses on the fundamental functions of nursing practice and the challenges encountered. The purpose of this review is to provide evidence to support the optimization of recovery protocols for patients undergoing breast surgery.
Impact of high-flux vs. conventional hemodialysis on clinical efficacy in patients with chronic renal failure (uremic stage) using real-world data.
Ge H, Zhang J, Yin G … +4 more , Han W, Wang Z, Li N, Li Y
Am J Transl Res · 2026 · PMID 42007136 · Full text
OBJECTIVE: Based on real-world data, this retrospective investigation discusses the impact of high-flux hemodialysis (HFHD) versus conventional hemodialysis (HD) on clinical outcomes in patients with chronic renal failur...
OBJECTIVE: Based on real-world data, this retrospective investigation discusses the impact of high-flux hemodialysis (HFHD) versus conventional hemodialysis (HD) on clinical outcomes in patients with chronic renal failure (CRF) of the uremic stage. METHODS: We selected 192 CRF (uremic stage) cases and conducted grouping based on intervention schemes: the HFHD group (n=100) received HFHD, while the HD group (n=92) received HD. We then conducted comparative analyses between the groups, with the dimensions covering: clinical efficacy; dialysis adequacy; toxin clearance efficiency; complications; inflammation; nutrition; bone metabolism (serum calcium [Ca], serum phosphorus [P], intact parathyroid hormone [iPTH]); and all-cause mortality. RESULTS: HFHD was associated with markedly higher therapeutic efficacy than HD. While demonstrating a dialysis adequacy equivalent to that of HD group, HFHD showed superior toxin clearance efficiency, induced fewer complications, and led to markedly lower one-year all-cause mortality rates. In addition, the post-interventional inflammatory markers, P, and iPTH of HFHD group displayed greater reductions compared to the control group, along with more pronounced increases in nutritional indices and Ca. CONCLUSION: HFHD outperforms conventional HD in clinical efficacy in managing uremic-stage CRF patients.
Swept-source optical coherence tomography quantitative scoring system accurately predicts postoperative intraocular pressure control and visual outcomes in primary angle-closure glaucoma.
Li H, Yao Z
Am J Transl Res · 2026 · PMID 42007135 · Full text
OBJECTIVE: To evaluate the clinical utility of the swept-source optical coherence tomography (SS-OCT) scoring system in the long-term management of primary angle-closure glaucoma (PACG). METHODS: Clinical data of 136 PAC...
OBJECTIVE: To evaluate the clinical utility of the swept-source optical coherence tomography (SS-OCT) scoring system in the long-term management of primary angle-closure glaucoma (PACG). METHODS: Clinical data of 136 PACG patients (155 eyes) who underwent phacoemulsification combined with goniosynechialysis between June 2021 and July 2023 were retrospectively analyzed. Based on intraocular pressure (IOP) one year postoperatively, patients were categorized into a controlled group (IOP < 21 mmHg, 85 patients, 98 eyes) and an uncontrolled group (IOP ≥ 21 mmHg, 51 patients, 57 eyes). SS-OCT was used to assess retinal nerve fiber layer (RNFL) thickness, optic disc parameters, Schlemm's canal morphology, angle opening distance at 500 μm (AOD500), trabecular-iris angle at 500 μm, and visual acuity. Logistic regression analysis was performed to identify factors influencing postoperative IOP control. RESULTS: The uncontrolled group showed higher IOP and lower RNFL thickness than the controlled group ( < 0.05). After treatment, the uncontrolled group exhibited higher cup-to-disc area ratio and diameter ratios than the controlled group ( < 0.05). Schlemm's canal diameter (SCD), Schlemm's canal area (SCA), and AOD500 were significantly lower in the uncontrolled group both before and after treatment ( < 0.05). Pre-treatment IOP was negatively correlated with SCD, SCA, and AOD500 ( < 0, < 0.05). Elevated IOP was identified as a risk factor for postoperative IOP control in PACG patients ( > 1, < 0.05). CONCLUSION: The SS-OCT scoring system accurately quantifies postoperative IOP control, RNFL thickness, optic disc parameters, and visual function changes in PACG patients, providing guidance for personalized treatment.
Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function.
Zhao S, Zhang J, Zhao Y
Am J Transl Res · 2026 · PMID 42007134 · Full text
OBJECTIVE: This study intended to clarify the role of metoprolol-spironolactone combination in treating coronary heart disease (CHD) with concurrent heart failure (HF), focusing on its impact on cardiac function. METHODS...
OBJECTIVE: This study intended to clarify the role of metoprolol-spironolactone combination in treating coronary heart disease (CHD) with concurrent heart failure (HF), focusing on its impact on cardiac function. METHODS: A total of 100 CHD + HF patients were selected, including 50 cases in the control group treated with spironolactone and 50 cases in the research group given metoprolol + spironolactone. Cardiac function (left ventricular end-systolic diameter [LVESd], left ventricular end-diastolic diameter [LVEDd], left ventricular ejection fraction [LVEF]), cardiac function classification, serum brain natriuretic peptide (BNP), oxidative stress (superoxide dismutase [SOD], malondialdehyde [MDA]), inflammation, hemodynamics (cardiac index/output), effectiveness, and safety were analyzed. RESULTS: The combination therapy induced a more evident reduction in LVESd, LVEDd, BNP, MDA, and two inflammatory cytokines than spironolactone alone, as well as a greater rise in LVEF, SOD, cardiac index, and cardiac output. The research group also showed superior improvements in cardiac function classification and clinical efficacy, as well as a lower overall adverse effect rate. CONCLUSION: Metoprolol-spironolactone combination is remarkably effective in treating CHD + HF and significantly improve patients' cardiac function, which merits clinical popularization.
Transradial cerebral angiography with SM2 catheter: a safe and effective alternative to the transfemoral approach.
Qiu T, Shi Q, Deng X … +3 more , Chen M, Fu S, Dai X
Am J Transl Res · 2026 · PMID 42007133 · Full text
OBJECTIVE: To compare the efficacy and safety of cerebral angiography performed using an SM2 catheter combined with a long guidewire exchange technique via transradial approach (TRA) versus the conventional transfemoral...
OBJECTIVE: To compare the efficacy and safety of cerebral angiography performed using an SM2 catheter combined with a long guidewire exchange technique via transradial approach (TRA) versus the conventional transfemoral approach (TFA). METHODS: Data from 853 patients who underwent diagnostic cerebral angiography between October 2019 and September 2020 were retrospectively reviewed. Patients were divided into a TRA group (n=425) and a TFA group (n=428) according to the vascular access route used. All procedures were performed by experienced neurointerventionalists following a standardized protocol on a uniform imaging system. Primary outcomes were the procedural success rate and the incidence of major complications within 24 hours after the procedure. Secondary outcomes included angiographic completeness, procedure time, fluoroscopy time, radiation dose, and the incidence of all complications during hospitalization. Multivariate logistic regression analysis was performed to adjust for potential confounding factors. RESULTS: The procedural success rate was high in both groups (TRA: 96.71% vs. TFA: 98.83%, P=0.035). Angiographic completeness was significantly higher in the TRA group than in the TFA group (99.27% vs. 87.00%, P < 0.001). Procedure time was shorter in the TRA group (32.4 ± 14.51 min vs. 42.54 ± 22.51 min, P < 0.001). There were no significant differences in fluoroscopy time or radiation dose. The overall complication rate was significantly lower in the TRA group (8.71% vs. 18.46%, P < 0.001), with no pseudoaneurysms observed in the TRA group versus 4.91% in the TFA group. CONCLUSIONS: The SM2 catheter with long guidewire exchange technique via the right radial artery is a safe and effective alternative to the conventional femoral approach for cerebral angiography. It offers shorter procedure times, higher angiographic completeness, and a significantly lower complication profile.
Hyperoside promotes osteoblast differentiation by increasing osteoclast-derived migrasomes to alleviate osteoporosis.
Yan S, Luo Z, Ma B … +3 more , Dou J, Liu L, Miao L
Am J Transl Res · 2026 · PMID 42007132 · Full text
OBJECTIVES: Osteoporosis, resulting from an imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption, can be alleviated by hyperoside. Migrasomes, as newly discovered extracellular ves...
OBJECTIVES: Osteoporosis, resulting from an imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption, can be alleviated by hyperoside. Migrasomes, as newly discovered extracellular vesicles, play a crucial role in mediating intercellular communication. However, it remains unclear whether hyperoside alleviates osteoporosis by mediating intercellular communication between osteoblasts and osteoclasts through migrasomes. This study investigates the potential therapeutic mechanisms of hyperoside in treating osteoporosis using an ovariectomized mouse model. METHODS: Hyperoside was administered to the mice by intragastric gavage daily for 2 months. Micro-CT scans and histopathological analyses were performed to evaluate bone formation. Migrasomes derived from hyperoside-treated osteoclasts were characterized by transmission electron microscopy, Western blot, and immunofluorescence, and subsequently used to treat osteoblasts followed by RNA sequencing. RESULTS: Micro-CT scans and histopathological evaluations showed that hyperoside reduced bone resorption and osteoclast numbers in ovariectomized mice. Immunofluorescence staining revealed that hyperoside increased the expression of osteoblast regulators OPG and RUNX2. Hyperoside increased migrasome secretion from osteoclasts, which was validated by transmission electron microscopy and Western blot analyses. Migrasomes were then used to treat MC3T3-E1 cells, boosting osteoblast marker expressions and differentiation. RNA sequencing of migrasomes showed distinct regulatory patterns, with upregulated genes in the hyperoside-treated migrasomes compared to the control linked to immune responses, iron ion homeostasis, oxidative stress, and apoptosis, and downregulated genes related to lipid metabolism. Notably, hyperoside-regulated migrasomes also affected ferroptosis by increasing ferroptosis repressors Nr4a1, Lcn2, Nupr1, and Zfp36. CONCLUSIONS: These findings suggest that hyperoside exerts its osteogenic effects through migrasome-mediated crosstalk, offering new insights into the treatment of osteoporosis.
Dabigatran outperforms warfarin in elderly patients with atrial fibrillation and stable coronary artery disease: reduced risks of bleeding and cardiovascular events.
Song L, Li N, Wang Z … +2 more , Yu J, Qin J
Am J Transl Res · 2026 · PMID 42007131 · Full text
OBJECTIVES: This study compares the safety of dabigatran versus warfarin in elderly patients with atrial fibrillation and stable coronary artery disease, who face higher stroke and bleeding risks due to anticoagulation n...
OBJECTIVES: This study compares the safety of dabigatran versus warfarin in elderly patients with atrial fibrillation and stable coronary artery disease, who face higher stroke and bleeding risks due to anticoagulation needs. METHODS: This retrospective cohort study included patients aged ≥ 65 years who initiated anticoagulation therapy between June 1, 2021 and June 2, 2024. Patients were divided into dabigatran and warfarin groups. Coagulation functions were assessed at baseline and one month post-treatment. Bleeding events and major adverse cardiovascular events were recorded over the 12-month follow-up. Treatment adherence was evaluated at one and three month intervals. RESULTS: A cohort of 218 patients was analyzed, with 102 in the dabigatran group and 116 in the warfarin group, showing comparable baseline characteristics. One month post-treatment, activated partial thromboplastin time was higher in the dabigatran group (42.11 vs. 40.89, P=0.007), while D-dimer levels were lower (0.55 vs. 0.58, P=0.003). The annual incidence rates of major bleeding (3.92% vs. 12.93%, P=0.019) and intracranial hemorrhage (0.98% vs. 7.76%, P=0.039) were significantly lower in the dabigatran group. Total bleeding events were also lower in the dabigatran group (16.67% vs. 31.90%, P=0.009). Dabigatran group showed reduced rates of ischemic stroke (0.98% vs. 7.76%, P=0.039) and acute myocardial infarction (1.96% vs. 8.62%, P=0.031). Good compliance at 3 months was higher in the dabigatran group (83.3% vs. 69.8%, P=0.020). CONCLUSIONS: In senior individuals with atrial fibrillation and stable coronary artery disease, dabigatran is associated with better control of thrombotic activity, lower bleeding risk, and a higher medication compliance compared to warfarin.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe